Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
Other Sizes |
|
Purity: ≥98%
Vecabrutinib (formerly SNS-062; FP-182, BSK-4841 and BIIB-062) is a novel, potent, and reversible/noncovalent BTK and ITK inhibitor with Kd of 0.3 nM and 2.2 nM, respectively; Vecabrutinib shows an IC50 of 24 nM for ITK. SNS-062 does not require interaction with BTK C481 for inhibitory activity. SNS-062 has improved PK properties over ibrutinib, including greater bioavailability and a longer half-life. SNS-062 may offer an alternative treatment option to patients with acquired resistance to ibrutinib.
ln Vitro |
In human whole blood, vecabrutinib inhibits pBTK with a mean IC50 of 50 nM. Similar IC50 values (pBTK IC50: WT BTK 2.9 nM, C481S BTK 4.4 nM) are observed for vecabrutinib's inhibition of WT and C481S BTK [1]. Vecabrutinib's IC50 against WT BTK and C481S BTK in recombinant kinase assays was 4.6 nM and 1.1 nM, respectively. Vecabrutinib continues to be active against BTK mutant forms. Vecabrutinib demonstrated dose-dependent suppression of BTK similar to PCI-32765 in primary patient CLL cells via BTK phosphorylation immunoblotting. Vecabrutinib was six times more effective than PCI-32765 and more than 640 times more potent than acalabrutinib against C481S BTK. Vecabrutinib decreases primary CLL cell survival by 5.5% when HS5 stromal protection is present [2].
|
---|---|
ln Vivo |
In rats and dogs, vecabrutinib exhibits a good oral bioavailability (%F > 40%) with a terminal half-life of five to six hours. At doses and durations much beyond PCI-32765, vecabrutinib was well tolerated [1].
|
References |
[1]. Minke E. Binnerts, et al. Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation. Molecular Cancer Therapeutics. December 2015 Volume 14, Issue 12 Supplement
[2]. Catherine A. Fabian, et al. Abstract 1207: SNS-062 demonstrates efficacy in chronic lymphocytic leukemia in vitro and inhibits C481S mutated Bruton tyrosine kinase. Cancer Research July 2017 Volume 77, Issue 13 Supplement |
Molecular Formula |
C22H24CLF4N7O2
|
---|---|
Molecular Weight |
529.918276786804
|
CAS # |
1510829-06-7
|
Related CAS # |
1270014-40-8 (SNS062-analog);1510829-06-7; 1947403-49-7;
|
SMILES |
O=C1N([C@H]2CN(C3=NC=NC(N)=C3F)CC[C@@H]2C(N)=O)CCC[C@H]1NC4=CC(C(F)(F)F)=CC(Cl)=C4
|
InChi Key |
QLRRJMOBVVGXEJ-XHSDSOJGSA-N
|
InChi Code |
InChI=1S/C22H24ClF4N7O2/c23-12-6-11(22(25,26)27)7-13(8-12)32-15-2-1-4-34(21(15)36)16-9-33(5-3-14(16)19(29)35)20-17(24)18(28)30-10-31-20/h6-8,10,14-16,32H,1-5,9H2,(H2,29,35)(H2,28,30,31)/t14-,15+,16-/m0/s1
|
Chemical Name |
(3R,3'R,4'S)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide
|
Synonyms |
SNS-062; SNS 062; SNS062; BSK-4841; BSK4841; BSK 4841; FP182; FP 182; FP-182; BIIB-062; BIIB062; BIIB 062
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~235.88 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.72 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.72 mM) (saturation unknown) in 5% DMSO + 95% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.08 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 5: ≥ 2.08 mg/mL (3.93 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8871 mL | 9.4354 mL | 18.8708 mL | |
5 mM | 0.3774 mL | 1.8871 mL | 3.7742 mL | |
10 mM | 0.1887 mL | 0.9435 mL | 1.8871 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.